NasdaqGS - Delayed Quote USD
Verve Therapeutics, Inc. (VERV)
At close: October 21 at 4:00 PM EDT
After hours: October 21 at 4:20 PM EDT
Insider Purchases Last 6 Months
Shares | Transactions | |
---|---|---|
Purchases | 0 | 0 |
Sales | -- | 0 |
Net Shares Purchased (Sold) | 0 | 0 |
Total Insider Shares Held | 1.51M | -- |
% Net Shares Purchased (Sold) | -- | -- |
Net Institutional Purchases Prior Quarter to Latest Quarter
Shares | |
---|---|
Net Shares Purchased (Sold) | -- |
% Change in Institutional Shares Held | -- |
Insider Transactions Reported - Last Two Years
Insider | Transaction | Type | Value | Date |
---|---|---|---|---|
KATHIRESAN SEKAR Chief Executive Officer | Conversion of Exercise of derivative security at price 2.87 per share. | Direct | 86,100 | Jun 28, 2024 |
ASHE ANDREW D President | Purchase at price 6.26 per share. | Direct | 475,760 | May 14, 2024 |
NICKERSON JOAN Officer | Sale at price 8.24 per share. | Direct | 12,475 | Apr 2, 2024 |
NICKERSON JOAN Officer | -- | Direct | -- | Apr 1, 2024 |
YESHWANT KRISHNA Director and Beneficial Owner of more than 10% of a Class of Security | Purchase at price 10.00 per share. | Indirect | 18,000,000 | Dec 1, 2023 |
DORVAL ALLISON Chief Financial Officer | Sale at price 11.45 per share. | Direct | 6,343 | Nov 29, 2023 |
DORVAL ALLISON Chief Financial Officer | -- | Direct | -- | Nov 29, 2023 |
ADELMAN BURT A Director | Stock Gift at price 0.00 per share. | Indirect | 0 | Sep 18, 2023 |
BELLINGER ANDREW Officer | Conversion of Exercise of derivative security at price 2.87 per share. | Direct | 103,320 | Dec 14, 2022 |
BELLINGER ANDREW Officer | Sale at price 22.95 per share. | Direct | 19,852 | Dec 1, 2022 |
DORVAL ALLISON Chief Financial Officer | Sale at price 22.10 per share. | Direct | 12,243 | Nov 29, 2022 |
DORVAL ALLISON Chief Financial Officer | -- | Direct | -- | Nov 29, 2022 |
YESHWANT KRISHNA Director and Beneficial Owner of more than 10% of a Class of Security | Sale at price 31.12 - 32.90 per share. | Indirect | 1,512,806 | Nov 4, 2022 |
GV 2017 GP, L.L.C. Beneficial Owner of more than 10% of a Class of Security | Sale at price 31.12 - 32.90 per share. | Indirect | 3,025,611 | Nov 4, 2022 |
YESHWANT KRISHNA Director and Beneficial Owner of more than 10% of a Class of Security | Sale at price 32.32 - 36.78 per share. | Indirect | 2,655,330 | Nov 3, 2022 |
GV 2017 GP, L.L.C. Beneficial Owner of more than 10% of a Class of Security | Sale at price 32.32 - 36.78 per share. | Indirect | 5,310,658 | Nov 3, 2022 |
YESHWANT KRISHNA Director and Beneficial Owner of more than 10% of a Class of Security | Sale at price 36.69 - 40.64 per share. | Indirect | 3,250,496 | Nov 1, 2022 |
GV 2017 GP, L.L.C. Beneficial Owner of more than 10% of a Class of Security | Sale at price 36.69 - 40.64 per share. | Indirect | 6,501,031 | Nov 1, 2022 |
BELLINGER ANDREW Officer | Sale at price 39.90 per share. | Direct | 399,000 | Oct 28, 2022 |
BELLINGER ANDREW Officer | Conversion of Exercise of derivative security at price 1.48 per share. | Direct | 14,800 | Oct 28, 2022 |
Related Tickers
BEAM Beam Therapeutics Inc.
23.15
-2.11%
CRBU Caribou Biosciences, Inc.
1.9700
-1.50%
PRME Prime Medicine, Inc.
4.3700
-0.23%
NTLA Intellia Therapeutics, Inc.
20.67
-1.94%
EDIT Editas Medicine, Inc.
3.7600
+11.90%
TNYA Tenaya Therapeutics, Inc.
1.9200
-5.88%
VYGR Voyager Therapeutics, Inc.
7.66
-5.08%
BLUE bluebird bio, Inc.
0.4968
+1.22%
OMGA Omega Therapeutics, Inc.
1.0700
+0.94%
SANA Sana Biotechnology, Inc.
3.9300
-7.09%